Viscosupplementation for osteoarthritis: A primer for primary care physicians

Advances in Therapy

Volumn 30, Issue 11, 2013, Pages 967-986

  Reid, M Carrington ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Hyaluronic acid; Intra articular injection; Osteoarthritis; Rheumatology; Viscosupplementation

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; EUFLEXXA; GEL ONE; GENZYME; HYALURONIC ACID; HYALURONIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG;

ARTHRALGIA; CARDIOVASCULAR DISEASE; CHONDROPATHY; CONSERVATIVE TREATMENT; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; GASTROINTESTINAL TOXICITY; HAND OSTEOARTHRITIS; HIP OSTEOARTHRITIS; HUMAN; INJECTION SITE PAIN; INJECTION SITE SWELLING; JOINT SWELLING; KNEE OSTEOARTHRITIS; KNEE PAIN; KNEE RADIOGRAPHY; LIVER TOXICITY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIMARY MEDICAL CARE; RETREATMENT; REVIEW; SHOULDER DISEASE; SYNOVITIS; TEMPOROMANDIBULAR JOINT DISORDER; VISCOSUPPLEMENTATION; AGED; ANKLE; DRUG EFFECTS; FEMALE; GENERAL PRACTITIONER; INTRAARTICULAR DRUG ADMINISTRATION; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PATIENT SAFETY; PRIMARY HEALTH CARE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SHOULDER; TEMPOROMANDIBULAR JOINT; TREATMENT OUTCOME;

AGED; ANKLE JOINT; FEMALE; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PATIENT SAFETY; PHYSICIANS, PRIMARY CARE; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SHOULDER JOINT; TEMPOROMANDIBULAR JOINT; TREATMENT OUTCOME; VISCOSUPPLEMENTATION;

EID: 84890127983     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0068-6     Document Type: Review

References (119)

1. A National Public Health Agenda for Osteoarthritis. Centers for Disease Control and Prevention. www.cdc.gov/arthritis/docs/OAagenda.pdf (2010). Accessed Aug 24, 2012.
2. Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-94. J Rheumatol. 2006;33:2271-9.
3. Brzusek D, Petron D. Treating knee osteoarthritis with intra-articular hyaluronans. Curr Med Res Opin. 2008;24:3307-22.
4. Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011;23:471-8.
5. Murphy L, Schwartz TA, Helmick CG, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthr Rheum. 2008;59:1207-13.
6. Hootman JM, Murphy LB, Helmick CG. Arthritis as a potential barrier to physical activity among adults with obesity - United States, 2007-2009. Morb Mortal Wkly Rep. 2011;60:614-5.
7. Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanism of action. Arthr Res Ther. 2003;5:54-67.
8. Bagga H, Burkhardt D, Sambrook P, March L. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol. 2006;33:946-50.
9. Balazs EA. Some aspects of the aging and radiation sensitivity of the intercellular matrix with special regard to hyaluronic acid in synovial fluid and vitreous. Aging Connect Skeletal Tissue 1969;107-22.
10. Felson DT, Gross KD, Nevitt MC, et al. The effects of impaired joint position sense on the development and progression of pain and structural damage in knee osteoarthritis. Arthr Rheum. 2009;61:1070-6.
11. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthr Care Res (Hoboken). 2012;64:465-74.
12. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil. 2010;18:476-99.
13. Altman R, Barkin RL. Topical therapy for osteoarthritis: clinical and pharmacologic perspectives. Postgrad Med. 2009;121:139-47.
14. Altman RD, Fowler PJ. Pharmacologic treatment of knee osteoarthritis in athletic women. Phys Sportsmed. 2011;39:39-44.
15. Schilling A, Corey R, Leonard M, Eghtesad B. Acetaminophen: old drug, new warnings. Cleve Clin J Med. 2010;77:19-27.
16. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634-42.
17. Chou R, Helfand M, Peterson K, Dana T, Roberts C. Drug class review on cyclo-oxygenase (COX)-2 inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs) final report update. Oregon Health and Science University; 2006.
18. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int. 2012;32:1491-502.
19. FDA acetaminophen announcement. Nevada Department of Health and Human Services. www.medicaid.nv.gov/Downloads/provider/web-announcement-468-20120425. pdf (2012). Accessed Oct 30, 2013.
20. FDA. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm150314.htm (2005). Accessed Mar 5, 2013.
21. Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthr Cartil. 2007;15:957-65.
22. Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2006;3:CD005522.
23. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170:1968-76.
24. FDA issues draft guidance on abuse-deterrent opioids. US Food and Drug Administration. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm334785.htm (2013). Accessed Mar 5, 2013.
25. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2005;2:CD005328.
26. Daly E, Gray A, Barlow D, Mcpherson K, Roche M, Vessey M. Measuring the impact of menopausal symptoms on quality of life. BMJ. 1993;307:836-40.
27. Balch HW, Gibson JM, El-Ghobarey AF, Bain LS, Lynch MP. Repeated corticosteroid injections into knee joints. Rheumatol Rehabil. 1977;16:137-40.
28. Tehranzadeh J, Booya F, Root J. Cartilage metabolism in osteoarthritis and the influence of viscosupplementation and steroid: a review. Acta Radiol. 2005;46:288-96.
29. ® (hylan G-F 20) Prescribing Information. Genzyme Biosurgery. http://synviscone.com/~/media/SynviscOneUS/Files/Synvisc- OnePI-70240104.pdf (2013). Accessed Mar 5, 2013.
30. ® (hylan G-F 20) Prescribing Information. Genzyme Biosurgery. http://synviscone.com/~/media/SynviscOneUS/Files/synvisc-PI.pdf (2013). Accessed Mar 5, 2013.
31. ® (1% sodium hyaluronate) Prescribing Information. Ferring Pharmaceuticals. www.euflexxa.com/assets/euflexxa-physician- f87c5c8e9b6f9317c6cfd0b7df1b48c6.pdf (2013). Accessed Mar 5, 2013.
32. ® (sodium hyaluronate) Prescribing Information. Sanofi-aventis. www.hyalgan.com/download/hyalgan-pi.pdf (2013). Accessed Mar 5, 2013.
33. ® (sodium hyaluronate) Prescribing Information. Seikagaku Corporation. http://supartzprofessional.com/docs/PackageInsert.pdf (2013). Accessed Mar 5, 2013.
34. ® (sodium hyaluronate) Prescribing Information. Anika Pharmaceuticals. www.orthoviscline.com/sites/default/files/file/Orthovisc- Package-Insert.pdf (2013). Accessed Mar 5, 2013.
35. ® (cross-linked hyaluronate) Prescribing Information. Seikagaku Corporation. www.zimmer.com/content/pdf/en-US/Gel-One- Pkg-Insert-Final.pdf (2013). Accessed Mar 5, 2013.
36. Rutjes AW, Juni P, da Costa BR, Trelle S, Nuesch E, Reichenbach S. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med. 2012;157:180-91.
37. Bannuru RR, Natov NS, Dasi UR, Schmid CH, McAlindon TE. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis - meta-analysis. Osteoarthr Cartil. 2011;19:611-9.
38. Goldberg VM, Goldberg L. Intra-articular hyaluronans: the treatment of knee pain in osteoarthritis. J Pain Res. 2010;3:51-6.
39. Grecomoro G, La Sala F, Francavilla G. Rheologic changes in the synovial fluid of patients with gonarthritis induced by intraarticular infiltration of hyaluronic acid. Int J Tissue React. 2001;23:67-71.
40. Wang Y, Hall S, Hanna F, et al. Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMC Musculoskelet Disord. 2011;12:195.
41. Creamer P, Sharif M, George E, et al. Intra-articular hyaluronic acid in osteoarthritis of the knee: an investigation into mechanisms of action. Osteoarthr Cartil. 1994;2:133-40.
42. Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res. 1994;55:220-32.
43. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998;20:410-23.
44. Karlsson J, Sjogren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology. 2002;41:1240-8.
45. Grecomoro G, Martorana U, Di Marco C. Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trial versus placebo. Pharmatherapeutica. 1987;5:137-41.
46. Dixon AS, Jacoby RK, Berry H, Hamilton EBD. Clinical trial of intra-articular injection of sodium hyaluronate in patients with osteoarthritis of the knee. Curr Med Res Opin. 1988;11:205-13.
47. Dougados M, Nguyen M, Listrat V, Amor B. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthr Cartil. 1993;1:97-103.
48. Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol. 1998;25:2203-12.
49. Puhl W, Bernau A, Greiling H, et al. Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter, double-blind study. Osteoarthr Cartil. 1993;1:233-41.
50. Lohmander LS, Dalen N, Englund G, et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. Ann Rheum Dis. 1996;55:424-31.
51. Day R, Brooks P, Conaghan PG, Petersen M. A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee. J Rheumatol. 2004;31:775-82.
52. Brandt KD, Block JA, Michalski JP, Moreland LW, Caldwell JR, Lavin PT. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. ORTHOVISC Study Group. Clin Orthop Relat Res. 2001;385:130-43.
53. Kotevoglu N, Iybozkurt PC, Hz O, Toktas H, Kuran B. A prospective randomized controlled clinical trial comparing the efficacy of different molecular weight hyaluronan solutions in the treatment of knee osteoarthritis. Rheumatol Int. 2006;26:325-30.
54. Neustadt D, Caldwell J, Bell M, Wade J, Gimbel J. Clinical effects of intraarticular injection of high molecular weight hyaluronan (Orthovisc) in osteoarthritis of the knee: a randomized, controlled, multicenter trial. J Rheumatol. 2005;32:1928-36.
55. Altman RD, Rosen JE, Bloch DA, Hatoum HT, Korner P. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). Semin Arthritis Rheum. 2009;39:1-9.
56. Tamir E, Robinson D, Koren R, Agar G, Halperin N. Intra-articular hyaluronan injections for the treatment of osteoarthritis of the knee: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol. 2001;19:265-70.
57. Altman RD, Rosen JE, Bloch DA, Hatoum HT. Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label Extension Study of the FLEXX Trial. Osteoarthr Cartil. 2011;19:1169-75.
58. Chevalier X, Jerosch J, Goupille P, et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis. 2010;69:113-9.
59. Strand V, Baraf HS, Lavin PT, Lim S, Hosokawa H. A multicenter, randomized controlled trial comparing a single intra-articular injection of Gel-200, a new cross-linked formulation of hyaluronic acid, to phosphate buffered saline for treatment of osteoarthritis of the knee. Osteoarthr Cartil. 2012;20:350-6.
60. Strand V, Barafat HSB, Lavin PT, Lim S, Hosokawa H. Effectiveness and safety of a multicenter extension and retreatment trial of Gel-200 in patients with knee osteoarthritis. Cartilage. 2012;3:297-304.
61. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee (review). Cochrane Database Syst Rev 2006;(2):CD005321.
62. Wang CT, Lin J, Chang CJ, Lin YT, Hou SM. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg Am. 2004;86-A:538-45.
63. Lo GH, LaValley M, McAlindon T, Felson DT. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA. 2003;290:3115-21.
64. Colen S, van den Bekerom MP, Mulier M, Haverkamp D. Hyaluronic acid in the treatment of knee osteoarthritis: a systematic review and meta-analysis with emphasis on the efficacy of different products. Biodrugs. 2012;26:257-68.
65. Arrich J, Piribauer F, Mad P, Schmid D, Klaushofer K, Mullner M. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ. 2005;172:1039-43.
66. Campbell J, Bellamy N, Gee T. Differences between systematic reviews/meta-analyses of hyaluronic acid/hyaluronan/hylan in osteoarthritis of the knee. Osteoarthr Cartil. 2007;15:1424-36.
67. Raman R, Dutta A, Day N, Sharma HK, Shaw CJ, Johnson GV. Efficacy of Hylan G-F 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee - a prospective randomized clinical trial. Knee. 2008;15:318-24.
68. Karatosun V, Unver B, Gocen Z, Sen A. Comparison of two hyaluronan drugs in patients with advanced osteoarthritis of the knee. A prospective, randomized, double-blind study with long term follow-up. Clin Exp Rheumatol. 2005;23:213-8.
69. Juni P, Reichenbach S, Trelle S, et al. Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthr Rheum. 2007;56:3610-9.
70. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthr Cartil. 2006;14:154-62.
71. Maheu E, Zaim M, Appelboom T, et al. Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non inferiority, prospective, randomized, controlled trial. Clin Exp Rheumatol. 2011;29:527-35.
72. Briggs KK, Matheny LM, Steadman JR. Can hylan G-F 20 with corticosteroid meet the expectations of osteoarthritis patients? Am J Orthop (Belle Mead NJ). 2012;41:311-5.
73. ® and repeat treatment for osteoarthritis pain in the knee. J Manag Care Med. 2010;13:43-7.
74. Kotz R, Kolarz G. Intra-articular hyaluronic acid: duration of effect and results of repeated treatment cycles. Am J Orthop. 1999;28(Suppl 11):5-7.
75. Raynauld JP, Goldsmith CH, Bellamy N, et al. Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis. Osteoarthr Cartil. 2005;13:111-9.
76. Scali JJ. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: a long-term study. Eur J Rheumatol Inflamm. 1995;15:57-62.
77. Waddell DD, Cefalu CA, Bricker DC. A second course of hylan G-F 20 for the treatment of osteoarthritic knee pain: 12-month patient follow-up. J Knee Surg. 2005;18:7-15.
78. Waddell DD. The tolerability of viscosupplementation: low incidence and clinical management of local adverse events. Curr Med Res Opin. 2003;19:575-80.
79. Caborn D, Rush J, Lanzer W, Parenti D, Murray C. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J Rheumatol. 2004;31:333-43.
80. Spitzer AI, Bockow BI, Brander VA, et al. Hylan G-F 20 improves hip osteoarthritis: a prospective, randomized study. Phys Sportsmed. 2010;38:35-47.
81. Migliore A, Tormenta S, Massafra U, et al. Intra-articular administration of hylan G-F 20 in patients with symptomatic hip osteoarthritis: tolerability and effectiveness in a large cohort study in clinical practice. Curr Med Res Opin. 2008;24:1309-16.
82. Migliore A, Bizzi E, Massafra U, Bella A. The impact of treatment with hylan G-F 20 on progression to total hip arthroplasty in patients with symptomatic hip OA: a retrospective study. Curr Med Res Opin. 2012;28:755-60.
83. Qvistgaard E, Christensen R, Torp-Pedersen S, Bliddal H. Intra-articular treatment of hip osteoarthritis: a randomized trial of hyaluronic acid, corticosteroid, and isotonic saline. Osteoarthr Cartil. 2006;14:163-70.
84. Carpenter B, Motley T. The role of viscosupplementation in the ankle using hylan G-F 20. J Foot Ankle Surg. 2008;47:377-84.
85. Witteveen AG, Giannini S, Guido G, et al. A prospective multi-centre, open study of the safety and efficacy of hylan G-F 20 (Synvisc) in patients with symptomatic ankle (talo-crural) osteoarthritis. Foot Ankle Surg. 2008;14:145-52.
86. Salk RS, Chang TJ, D'Costa WF, Soomekh DJ, Grogan KA. Sodium hyaluronate in the treatment of osteoarthritis of the ankle: a controlled, randomized, double-blind pilot study. J Bone Joint Surg Am. 2006;88:295-302.
87. Cohen MM, Altman RD, Hollstrom R, Hollstrom C, Sun C, Gipson B. Safety and efficacy of intra-articular sodium hyaluronate (Hyalgan) in a randomized, double-blind study for osteoarthritis of the ankle. Foot Ankle Int. 2008;29:657-63.
88. Sun SF, Hsu CW, Sun HP, Chou YJ, Li HJ, Wang JL. The effect of three weekly intra-articular injections of hyaluronate on pain, function, and balance in patients with unilateral ankle arthritis. J Bone Joint Surg Am. 2011;93:1720-6.
89. Witteveen AG, Sierevelt IN, Blankevoort L, Kerkhoffs GM, van Dijk CN. Intra-articular sodium hyaluronate injections in the osteoarthritic ankle joint: effects, safety and dose dependency. Foot Ankle Surg. 2010;16:159-63.
90. Figen Ayhan F, Üstun N. The evaluation of efficacy and tolerability of hylan G-F 20 in bilateral thumb base osteoarthritis: 6 months follow-up. Clin Rheumatol. 2009;28:535-41.
91. Mandl LA, Hotchkiss RN, Adler RS, et al. Injectable hyaluronan for the treatment of carpometacarpal osteoarthritis: open label pilot trial. Curr Med Res Opin. 2009;25:2103-8.
92. Heyworth BE, Lee JH, Kim PD, Lipton CB, Strauch RJ, Rosenwasser MP. Hylan versus corticosteroid versus placebo for treatment of Basal joint arthritis: a prospective, randomized, double-blinded clinical trial. J Hang Surg Am. 2008;33:40-8.
93. Stahl S, Karsh-Zafrir I, Ratzon N, Rosenberg N. Comparison of intraarticular injection of depot corticosteroid and hyaluronic acid for treatment of degenerative trapeziometacarpal joints. J Clin Rheumatol. 2005;11:299-302.
94. Schumacher HR, Meador R, Sieck M, Mohammed Y. Pilot investigation of hyaluronate injections for first metacarpal-carpal (MC-C) osteoarthritis. J Clin Rheumatol. 2004;10:59-62.
95. Bjornland T, Gjaerum AA, Moystad A. Osteoarthritis of the temporomandibular joint: an evaluation of the effects and complications of corticosteroid injection compared with injection with sodium hyaluronate. J Oral Rehabil. 2007;34:583-9.
96. Manfredini D, Bonnini S, Arboretti R, Guarda-Nardini L. Temporomandibular joint osteoarthritis: an open label trial of 76 patients treated with arthrocentesis plus hyaluronic acid injections. Int J Oral Maxillofac Surg. 2009;38:827-34.
97. Saito S, Furuya T, Kotake S. Therapeutic effects of hyaluronate injections in patients with chronic painful shoulder: a meta-analysis of randomized controlled trials. Arthr Care Res (Hoboken). 2010;62:1009-18.
98. Brander VA, Gomberawalla A, Chambers M, Bowen M, Nuber G. Efficacy and safety of hylan G-F 20 for symptomatic glenohumeral osteoarthritis: a prospective, pilot study. PM R. 2010;2:259-67.
99. Merolla G, Sperling JW, Paladini P, Porcellini G. Efficacy of Hylan G-F 20 versus 6-methylprednisolone acetate in painful shoulder osteoarthritis: a retrospective controlled trial. Musculoskelet Surg. 2011;95:215-24.
100. Silverstein E, Leger R, Shea KP. The use of intra-articular hylan G-F 20 in the treatment of symptomatic osteoarthritis of the shoulder: a preliminary study. Am J Sports Med. 2007;35:979-85.
101. Blaine T, Moskowitz R, Udell J, et al. Treatment of persistent shoulder pain with sodium hyaluronate: a randomized, controlled trial. A multicenter study. J Bone Joint Surg Am. 2008;90:970-9.
102. Langworthy MJ, Saad A, Langworthy NM. Conservative treatment modalities and outcomes for osteoarthritis: the concomitant pyramid of treatment. Phys Sportsmed. 2010;38:133-45.
103. Raynauld JP, Torrance G, Band P, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthr Cartil. 2002;10:506-17.
104. Kahan A, Lleu PL, Salin L. Prospective randomized study comparing the medicoeconomic benefits of hylan G-F 20 vs. conventional treatment in knee osteoarthritis. Joint Bone Spine. 2003;70:276-81.
105. Brander VA, Stadler TS. Functional improvement with hylan G-F 20 in patients with knee osteoarthritis. Phys Sportsmed. 2009;37:38-48.
106. Karatosun V, Unver B, Gocen Z, Sen A, Gunal I. Intra-articular hyaluronic acid is compared with progressive knee exercises in osteoarthritis of the knee: a prospective randomized trial with long-term follow-up. Rheumatol Int. 2006;26:277-84.
107. Atamaz F, Kirazli Y, Akkoc Y. A comparison of two different intra-articular hyaluronan drugs and physical therapy in the management of knee osteoarthritis. Rheumatol Int. 2006;26:873-8.
108. Lee SC, Rha DW, Chang WH. Rapid analgesic onset of intra-articular hyaluronic acid with ketorolac in osteoarthritis of the knee. J Back Musculoskelet Rehabil. 2011;24:31-8.
109. de Campos GC, Rezende MU, Pailo AF, Frucchi R, Camargo OP. Adding triamcinolone improves viscosupplementation: a randomized clinical trial. Clin Orthop Relat Res. 2013;471:613-20.
110. Neustadt DH. Long-term efficacy and safety of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee. Clin Exp Rheumatol. 2003;21:307-11.
111. Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Medicis R. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol. 1996;23:1579-85.
112. Waddell DD, Bricker DC. Hylan G-F 20 tolerability with repeat treatment in a large orthopedic practice: a retrospective review. J Surg Orthop Adv. 2006;15:53-9.
113. Evanich JD, Evanich CJ, Wright MB, Rydlewicz JA. Efficacy of intraarticular hyaluronic acid injections in knee osteoarthritis. Clin Orthop Relat Res 2001;390:173-81.
114. Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21:1261-9.
115. Dickson DJ, Hosie G, English JR. A double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. J Clin Res. 2001;4:41-52.
116. Kean WF, Rainsford KD, Kean IR. Management of chronic musculoskeletal pain in the elderly: opinions on oral medication use. Inflammopharmacology. 2008;16:53-75.
117. ®): pain and mobility observations from 74 consecutive patients. J Knee Surg. 2004;17:73-7.
118. Waddell DD, Bricker D. Clinical experience with the effectiveness and tolerability of hylan G-F 20 in 1047 patients with osteoarthritis of the knee. J Knee Surg. 2006;19:19-27.
119. Bannuru RR, Natov NS, Obadan IE, Price LL, Schmid CH, McAlindon TE. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthr Rheum. 2009;61:1704-11.